Press Release Archive
Press Releases
January 2024
01.10.2024 Financial Finance Pfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation 01.09.2024 Prescription Medicines Medicines TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer 01.08.2024 Prescription Medicines Medicines European Commission Approves Pfizer’s TALZENNA® in Combination with XTANDI® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer 01.02.2024 Financial Finance Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
December 2023
12.19.2023 Financial Finance Pfizer Invites Public to View and Listen to Webcast of January 30 Conference Call with Analysts 12.15.2023 Prescription Medicines Medicines PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer 12.14.2023 Financial Finance Pfizer Declares First-Quarter 2024 Dividend 12.14.2023 Corporate Investments Pfizer Completes Acquisition of Seagen 12.13.2023 Financial Finance Pfizer Provides Full-Year 2024 Guidance 12.12.2023 Corporate Financial Investments Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen 12.11.2023 FDA and EMA Accept Marstacimab Regulatory Submissions for the Treatment of Hemophilia A and B 12.09.2023 Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B
Media Resources & Contact Information
Anyone may view our press releases, press statements, and press kits.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.